Eyegate Pharmaceuticals Pharmaceuticals Healthcare: Ken Research
EyeGate Pharmaceuticals Inc (EYEG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

EyeGate Pharmaceuticals Inc (EYEG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH16499D
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

EyeGate Pharmaceuticals Inc (EyeGate) is a late-stage specialty pharmaceutical and drug delivery company that focus on developing and commercializing products for treating diseases and disorders of the eye. The company's proprietary technology EyeGate II delivery system, which utilizes transscleral iontophoresis to deliver optimal therapeutic levels of drug directly into the targeted ocular tissue; and CMHA-S platform, which is based on hyaluronic acid (HA), a naturally occurring polymer that is important in many physiological processes such as development, wound healing, tissue homeostasis and joint lubrication. The company offers EGP-437 that incorporates a reformulated corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues. It also offers drug delivery mechanisms for treating diseases of the eye. EyeGate is headquartered in Waltham, Massachusetts, the US.

EyeGate Pharmaceuticals Inc (EYEG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

EyeGate Pharma Raises USD2.6 Million in Venture Financing 13

EyeGate Pharma Raises USD1 Million in Venture Financing 14

Jade Therapeutics To Raise USD 0.6 Million In Venture Financing 15

EyeGate Pharma Raises USD 1 Million In Venture Financing 16

Partnerships 17

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 17

Licensing Agreements 19

EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 19

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 20

BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 21

Equity Offering 22

EyeGate Pharma Raises USD11.25 Million in Public Offering of Shares and Warrants 22

EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 24

EyeGate Pharma Raises USD3.8 Million in Private Placement of Shares and Preferred Stock 25

EyeGate Pharma Raises USD10 Million in Public Offering of Shares 27

EyeGate Pharma Raises USD4.1 Million in IPO 29

Acquisition 31

Eyegate Pharma Acquires Jade Therapeutics 31

EyeGate Pharmaceuticals Inc-Key Competitors 32

EyeGate Pharmaceuticals Inc-Key Employees 33

EyeGate Pharmaceuticals Inc-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Financial Announcements 35

Mar 02, 2018: EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update 35

Nov 14, 2017: EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 37

Aug 07, 2017: EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 39

May 08, 2017: EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 40

Feb 23, 2017: EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update 42

Corporate Communications 43

Jan 04, 2018: EyeGate Promotes Sarah Romano to Chief Financial Officer 43

Nov 01, 2017: EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy 44

Oct 23, 2017: Eye Care Thought Leaders Join EyeGate Scientific Advisory Board 45

Feb 06, 2017: EyeGate Pharmaceuticals Announces Executive Promotions 46

Product News 47

05/22/2017: EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients 47

03/13/2017: EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D. 48

Clinical Trials 49

Feb 05, 2018: EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery 49

Dec 19, 2017: EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye 50

Dec 18, 2017: EyeGate Achieves 75% Enrollment in Pivotal Phase III Clinical Trial for Anterior Uveitis Triggering Milestone Payment 51

Nov 08, 2017: EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery 52

Aug 01, 2017: EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

EyeGate Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

EyeGate Pharma Raises USD2.6 Million in Venture Financing 13

EyeGate Pharma Raises USD1 Million in Venture Financing 14

Jade Therapeutics To Raise USD 0.6 Million In Venture Financing 15

EyeGate Pharma Raises USD 1 Million In Venture Financing 16

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 17

EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 19

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 20

BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 21

EyeGate Pharma Raises USD11.25 Million in Public Offering of Shares and Warrants 22

EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 24

EyeGate Pharma Raises USD3.8 Million in Private Placement of Shares and Preferred Stock 25

EyeGate Pharma Raises USD10 Million in Public Offering of Shares 27

EyeGate Pharma Raises USD4.1 Million in IPO 29

Eyegate Pharma Acquires Jade Therapeutics 31

EyeGate Pharmaceuticals Inc, Key Competitors 32

EyeGate Pharmaceuticals Inc, Key Employees 33

EyeGate Pharmaceuticals Inc, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

EyeGate Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com